Volcano plot of gene differentially expressed between statin users and non-users.

<p>The plot shows the log fold-change on the X-axis versus the unadjusted P values (on the–log10 scale) on the Y-axis. The blue and red dots represent genes that showed fold change in either direction that is greater than 0.05 and have unadjusted P value <0.01. Genes that had an FDR-adjusted P value less than 0.05 for differential expression are annotated on the graph.</p

GO biological processes’ enrichment among statin differentially expressed genes.

<p>Adjusted P value: The Benjamini Hochberg Adjusted P value. No. of genes: number of genes in this pathway present among the 18 genes tested.</p><p>GO biological processes’ enrichment among statin differentially expressed genes.</p

Statins’ differentially expressed genes at 10% FDR.

<p>LogFC: log 2 fold change. Adj.p.value: Benjamini Hochberg Adjusted P value</p><p>Statins’ differentially expressed genes at 10% FDR.</p

Study participants’ demographics.

<p>Continuous variables are shown as mean+ standard error of man (SEM). Difference in demographics between statin users and non-users was calculated using Student’s t-test for continuous variables and Chi-square test for categorical variables</p><p>Study participants’ demographics.</p

Summary of logistic regression for persistent systemic inflammation (defined as in upper quartile at both visits for at least 2 biomarkers).

<p>Statistically significant factors are highlighted in bold. For further explanations, see text.</p

Box plot (log scale) of the different biomarkers determined at baseline in COPD patients, smokers with normal lung function and nonsmokers.

<p>For further explanations, see text.</p

Proportion of patients with none, one, or two (or more) biomarkers (WBC count, CRP, IL-6 and fibrinogen) in the upper quartile of the COPD distribution, at baseline (left bars) and after one year follow up (right bars).

<p>For further explanations, see text.</p

Comparison of baseline demographics, clinical, physiological and imaging characteristics of COPD patients with none or two (or more) biomarker levels in the upper quartile of the COPD distribution both at baseline and at one year follow-up.

<p>NS: non-significant.</p